238 related articles for article (PubMed ID: 27068947)
1. Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?
Alonso-Camino V; Harwood SL; Álvarez-Méndez A; Alvarez-Vallina L
Biochem Soc Trans; 2016 Apr; 44(2):406-11. PubMed ID: 27068947
[TBL] [Abstract][Full Text] [Related]
2. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
[TBL] [Abstract][Full Text] [Related]
3. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
4. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
Ebert LM; Yu W; Gargett T; Brown MP
Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Gross G; Eshhar Z
Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
[TBL] [Abstract][Full Text] [Related]
6. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells.
Navai SA; Ahmed N
Biochem Soc Trans; 2016 Apr; 44(2):391-6. PubMed ID: 27068945
[TBL] [Abstract][Full Text] [Related]
7. Development of CAR T cells designed to improve antitumor efficacy and safety.
Jaspers JE; Brentjens RJ
Pharmacol Ther; 2017 Oct; 178():83-91. PubMed ID: 28342824
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
9. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
11. Programming CAR-T cells to kill cancer.
Labanieh L; Majzner RG; Mackall CL
Nat Biomed Eng; 2018 Jun; 2(6):377-391. PubMed ID: 31011197
[TBL] [Abstract][Full Text] [Related]
12. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.
Xu J; Tian K; Zhang H; Li L; Liu H; Liu J; Zhang Q; Zheng J
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1099-1106. PubMed ID: 29048935
[TBL] [Abstract][Full Text] [Related]
14. Donor-derived CD19 chimeric antigen receptor T cells.
Singh N; Barrett DM
Curr Opin Hematol; 2015 Nov; 22(6):503-8. PubMed ID: 26457962
[TBL] [Abstract][Full Text] [Related]
15. The integrin αvβ6: a novel target for CAR T-cell immunotherapy?
Whilding LM; Vallath S; Maher J
Biochem Soc Trans; 2016 Apr; 44(2):349-55. PubMed ID: 27068939
[TBL] [Abstract][Full Text] [Related]
16. Co-opting signalling molecules enables logic-gated control of CAR T cells.
Tousley AM; Rotiroti MC; Labanieh L; Rysavy LW; Kim WJ; Lareau C; Sotillo E; Weber EW; Rietberg SP; Dalton GN; Yin Y; Klysz D; Xu P; de la Serna EL; Dunn AR; Satpathy AT; Mackall CL; Majzner RG
Nature; 2023 Mar; 615(7952):507-516. PubMed ID: 36890224
[TBL] [Abstract][Full Text] [Related]
17. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.
Flugel CL; Majzner RG; Krenciute G; Dotti G; Riddell SR; Wagner DL; Abou-El-Enein M
Nat Rev Clin Oncol; 2023 Jan; 20(1):49-62. PubMed ID: 36418477
[TBL] [Abstract][Full Text] [Related]
18. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.
Yeku OO; Brentjens RJ
Biochem Soc Trans; 2016 Apr; 44(2):412-8. PubMed ID: 27068948
[TBL] [Abstract][Full Text] [Related]
19. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
20. Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery.
Karlsson H
Biochem Soc Trans; 2016 Apr; 44(2):371-6. PubMed ID: 27068942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
